ライフサイエンスコーパス: tumor-bearing

1 umor growth in an EZH2-dependent manner, and tumors bearing a non-GNA-interacting C668S-EZH2 mutation

2 (MAPK) kinase (MEK) can induce regression of tumors bearing activating mutations in the Ras pathway b

3 d with (64)Cu, and administered to normal or tumor-bearing aged, female, retired breeder Sprague-Dawl

4 Importantly, TNF blockade in tumor-bearing, aged mice receiving IT displayed signific

5 Bone marrow and splenic cells extracted from tumor-bearing and control mice (n= 3/group) were coincub

6 sing (18)F-FDG was successfully performed on tumor-bearing and non-tumor-bearing mice, as well as on

7 delivery at alternative days for 4 weeks to tumor bearing animals.

8 line uptake of (18)F-AH113804, determined in tumor-bearing animals after 10 d, was approximately 2-fo

9 early as 6 d after surgery in the recurrent tumor-bearing animals and exhibited significantly higher

10 d cells were isolated from either healthy or tumor-bearing animals and injected into tumor-bearing mi

11 odistribution and in vivo PET imaging in non-tumor-bearing animals as well as in KB-3-1 and COLO-205

12 In vivo, PF-04691502 treatment of tumor-bearing animals resulted in a transient lymphocyto

13 Lymphoma xenograft tumor-bearing animals treated with doses of up to 48 mic

14 Tumor-bearing animals were coinjected with (18)F-EF5 and

15 ng tumor cells were significantly reduced in tumor-bearing animals when treated with anti-IL6R antibo

16 t manner, modulated cytokine blood levels in tumor-bearing animals, and impaired tumor progression vi

17 Tumor-bearing animals, while exhibiting increased angiog

18 gh-affinity CD8 T cells prolongs survival of tumor-bearing animals.

19 significantly undersampled imaging data from tumor-bearing animals.

20 effects of irradiation on TAMs and MDSCs in tumor-bearing animals.

21 Specifically, 3D models of tumor-bearing bone segments were constructed by using co

22 were evaluated in murine B16F10 subcutaneous tumor-bearing C57BL/6 mice.

23 es were performed using CD-1 nu/nu and LNCaP tumor-bearing CB-17 severe combined immunodeficiency mic

24 distribution studies were performed in LNCaP tumor-bearing CD-1 nu/nu mice.

25 mpared with that seen in WT littermates, but tumor-bearing CLEC14A-KO mice died sooner.

26 r abnormalities and enhanced the survival of tumor-bearing CLEC14A-KO mice.

27 milar to non-targeted liposomes in syngeneic tumor-bearing FVB mice and C-LPP liposomes reduced doxor

28 uced by experimenter-induced movement of the tumor-bearing hindlimb with a context produces condition

29 DCs in tumor-bearing hosts accumulate lipid bodies (LB) contain

30 id-derived suppressor cells (MDSC) expand in tumor-bearing hosts and play a central role in cancer im

31 Furthermore, reovirus administration in tumor-bearing hosts drives time-dependent recruitment of

32 oup of immature myeloid cells that expand in tumor-bearing hosts in response to soluble factors produ

33 bone marrow and secondary lymphoid organs of tumor-bearing hosts remain unclear.

34 We hypothesized that NO producing MDSC in tumor-bearing hosts would inhibit DC antigen presentatio

35 cient in their ability to accumulate MDSC in tumor-bearing hosts, demonstrated reduced MDSC accumulat

36 these effects reduced mMDSC accumulation in tumor-bearing hosts, limiting the outgrowth of KRas-driv

37 activity is reduced in peripheral tissues of tumor-bearing hosts.

38 e targets for innovative approaches to treat tumor-bearing hosts.

39 ed changes in TRAIL-R expression observed in tumor-bearing hosts.

40 DSCs from tumor-bearing mice compared to non-tumor-bearing hosts.

41 feel that this approach should be tested in tumor-bearing human patients in combination with antitum

42 ALT-803 lost its antimyeloma activity in tumor-bearing IFN-gamma knockout mice but retained the a

43 optive transfer of T cells from DLL1-treated tumor-bearing immunocompetent hosts into tumor-bearing S

44 tribution studies were performed using HT-29 tumor-bearing immunocompromised mice.

45 CD8 T cells were adoptively transferred into tumor-bearing immunocompromised SmoA1 recipients.

46 s (MDSC) contribute to immune suppression in tumor-bearing individuals and are a major obstacle to ef

47 a steady-state level of circulating MDSC in tumor-bearing individuals.

48 rmacologic inhibition of the PI3K pathway in tumor-bearing Kit(V558Delta/+) mice with the dual PI3K/m

49 an be used to ablate target tissues in a non-tumor-bearing large-animal model while selectively spari

50 bone fracture, and increased the use of the tumor-bearing limb.

51 e of lung metastasis after amputation of the tumor-bearing limb.

52 (FLR), portal vein embolization (PVE) of the tumor-bearing liver is used to induce contralateral live

53 breast adenocarcinoma tumors had normal non-tumor-bearing liver treated with RFA (70 degrees C x 5 m

54 ystemically delivering TTK siRNAs to already tumor-bearing liver, limits intrahepatic spread of liver

55 and lymphocytic infiltration of inflamed or tumor-bearing lung.

56 Tumor-bearing lungs of 5-LO-KO had decreased numbers of

57 s, macrophages, and regulatory T cells, into tumor-bearing lungs.

58 In vivo characterization using tumor-bearing male mice was performed by PET/CT for (86)

59 stribution of (18)F-LMI1195 was evaluated in tumor-bearing MENX mut/mut rats (n = 10) and control MEN

60 nd lymphocyte proliferation was increased in tumor-bearing MerTK-/- mice compared with tumor-bearing

61 tion of p-Akt in PTEN-deficient PC3 prostate tumor bearing mice after oral administration and showed

62 PDLA micelles or nanoemulsions to pancreatic tumor bearing mice resulted in complete tumor resolution

63 Treatment of WAP-Int3 tumor bearing mice with an IKK inhibitor resulted in tum

64 Treatment of tumor bearing mice with systemic administration of IL-12

65 In DU145 tumor bearing mice, a single treatment of tumor hyperthe

66 r intravenous treatment of RDLPNPs into Hela tumor bearing mice, fluorescent (from DiR) and enhanced

67 In tumor bearing mice, oral administration of 71 causes rap

68 was demonstrated in D54 glioma and A549 lung tumor bearing mice.

69 of drug resistance was studied in pancreatic tumor bearing mice.

70 v. injection of the payload loaded HA NPs in tumor bearing mice.

71 Remarkably, in C26-tumor-bearing mice (+)-JQ1 administration dramatically p

72 umumab- versus IgG1-treated COLO205 and HT29 tumor-bearing mice (P = 0.104 and 0.779, respectively) a

73 ssing VEGF-B or control vector to normal and tumor-bearing mice 1 wk before DOX treatment, using dose

74 enerated a 2.4-fold enhancement in signal in tumor-bearing mice 2 h postinjection.

75 or-infiltrating PD-L1(+) cells isolated from tumor-bearing mice also exerted morphology of tumor-asso

76 he peptide hormone Angiotensin II (AngII) in tumor-bearing mice amplifies self-renewing hematopoietic

77 ite elevated plasma levels of VEGFA in fs120 tumor-bearing mice and a dependence on VEGF receptor 1 a

78 eloid-derived suppressor cells in spleens of tumor-bearing mice and ex vivo.

79 n be detected in EVs purified from plasma of tumor-bearing mice and from conditioned media of culture

80 e fluorescence guidance were investigated in tumor-bearing mice and healthy pigs.

81 R5 ligand interactions increased survival of tumor-bearing mice and was associated with reduced migra

82 ell visualized by SPECT/CT imaging of AR4-2J tumor-bearing mice at 4 h after injection.

83 did not affect circulating levels of MDSC in tumor-bearing mice because the decreased apoptotic rate

84 a dose- and time-dependent manner in D54-CR tumor-bearing mice but not in PBS-treated mice.

85 onsistently upregulated in TLR5-unresponsive tumor-bearing mice but only accelerates malignant progre

86 ry differentiation of therapeutic T cells in tumor-bearing mice by introducing molecular switches tha

87 tudy, we demonstrate that IL-2c treatment in tumor-bearing mice can enhance NK cell and tumor-specifi

88 sion was significantly reduced in MDSCs from tumor-bearing mice compared to non-tumor-bearing hosts.

89 greater antitumor efficacy in EG.7 and TC-1 tumor-bearing mice compared to the control (p < 0.01).

90 d lower viability and a shorter half-life in tumor-bearing mice compared with neutrophils and monocyt

91 Studies conducted in tumor-bearing mice confirmed the deleterious effect of r

92 administration of the bioorthogonal IONPs in tumor-bearing mice demonstrated the signal-enhancing abi

93 In this host strain, tumor-bearing mice displayed increased growth of ectopic

94 Administration of CD5-2 in tumor-bearing mice enhanced expression of VE-cadherin in

95 ng larger tumors, the Arg-knockdown (Arg KD) tumor-bearing mice exhibit significant reductions in tum

96 Dendritic cells (DCs) from NK cell-depleted tumor-bearing mice exhibited a more mature phenotype.

97 DOX-loaded vesicles injected into 4T1 tumor-bearing mice exhibited enhanced accumulation in tu

98 than non-tumor-bearing mice, suggesting that tumor-bearing mice experience a greater degree of cold-s

99 that the pan-BET inhibitor (+)-JQ1 protects tumor-bearing mice from body weight loss and muscle and

100 We found that tumor-bearing mice had a relative increase in numbers of

101 n occupancy and gene expression in young and tumor-bearing mice identified a set of shared targets fo

102 Tumor-bearing mice implanted with A431-GFP, MDAMB468-GFP

103 siRNA-mediated LPP silencing in ovarian tumor-bearing mice improved paclitaxel delivery to cance

104 plore the function of salivary exosomes from tumor-bearing mice in immune surveillance.

105 c model and improved the overall survival of tumor-bearing mice in the GL26 syngeneic glioma model.

106 Depletion of CD8(+) T cells or NK cells in tumor-bearing mice indicates that both cell types initia

107 he increased production of angiotensin II in tumor-bearing mice induces the expansion of macrophage p

108 Non-invasive PET scans were acquired in tumor-bearing mice injected with (89)Zr-Df-ALT-836.

109 at doxorubicin (DOX) treatment of 4T1 breast tumor-bearing mice led to the induction of IL-13R(+)miR-

110 generated by treating HER2(+)/PIK3CA(H1047R) tumor-bearing mice long term with the drug combination.

111 tested in cynomolgus monkeys and pancreatic tumor-bearing mice models, respectively.

112 as prepared and evaluated in U87MG cells and tumor-bearing mice models.

113 Saliva exosomes from pancreatic tumor-bearing mice modulate NK cell phenotype and antitu

114 h increased monoclonal (M) protein (g/dL) in tumor-bearing mice over time (3.29 +/- 0.58 at week 0 an

115 Therapeutic vaccination of tumor-bearing mice reduced tumor vascularity, increased

116 Anti-PD-L1 treatment of tumor-bearing mice results in cessation of tumor growth

117 positive PC-3 PIP and PSMA-negative PC-3 flu tumor-bearing mice revealed that (86)Y- 4-6: had high si

118 ongitudinal analysis of circulating ALCAM in tumor-bearing mice revealed that shedding of tumor, but

119 ing lymph nodes of IL-12 plus GM-CSF-treated tumor-bearing mice revealed that whereas IFN-gamma induc

120 Notably, in temperature preference studies, tumor-bearing mice select a higher ambient temperature t

121 The L-band EPR studies performed in breast tumor-bearing mice show a significant difference in extr

122 SPECT images of tumor-bearing mice showed a significant increase in upta

123 Peritoneal lavage fluids from CREB-inhibited tumor-bearing mice showed a significantly reduced total

124 Biodistribution studies using HT29 tumor-bearing mice showed highest tumor uptake for [(68)

125 jugated Au-tripods (RGD-Au-tripods) to U87MG tumor-bearing mice showed PAI contrasts in tumors almost

126 Testing in tumor-bearing mice showed that PTX-NCs treated with Plur

127 stration of PNC-gel extended the survival of tumor-bearing mice significantly better than Taxol, but

128 Tumor-bearing mice specifically lacking L1 in endothelia

129 Administration of B-I09 to CLL tumor-bearing mice suppressed leukemic progression by in

130 esultant FA-3DNA-siHuR conjugates to ovarian tumor-bearing mice suppressed tumor growth and ascites d

131 tumor growth and significantly prolonged the tumor-bearing mice survival.

132 hat SGG colonization is 1,000-fold higher in tumor-bearing mice than in normal mice.

133 extracellular traps (NET), in the kidneys of tumor-bearing mice that were completely absent from heal

134 Furthermore, tumor-bearing mice that were FasL-deficient displayed an

135 one marrow-derived cells (BMDCs), we exposed tumor-bearing mice to chemotherapeutic agents and evalua

136 logy model of VEGF transport and kinetics in tumor-bearing mice to include a tumor compartment whose

137 QS Salmonella were injected into 4T1 tumor-bearing mice to quantify GFP expression in vivo us

138 nosuppressed (Nu/Nu) squamous cell carcinoma tumor-bearing mice treated post-IR with the constitutive

139 55.6% of tumor-bearing mice treated with MHIRE were tumor-free, w

140 In contrast, the p53-negative tumor-bearing mice treated with radioimmunotherapy alone

141 l as their efficacy in extending survival in tumor-bearing mice underscores their potential as a radi

142 APRPG-miR-499 were injected into tumor-bearing mice via a tail vein, and these lipoplexes

143 percentage injected dose per gram) in LNCaP tumor-bearing mice was observed.

144 claudin-low tumors, and Tregs isolated from tumor-bearing mice were able to suppress effector T cell

145 Experiments in cell cultures as well as in tumor-bearing mice were analyzed to determine the role o

146 When tumor-bearing mice were given hNIS- and hSSR2-containing

147 Strikingly, when tumor-bearing mice were immunodepleted of T lymphocytes

148 For CL-activated tagging in vivo, tumor-bearing mice were injected first with (90)Y-DOTA-R

149 Tumor-bearing mice were randomized into trebananib or ve

150 e tumor size reached 0.5-0.8 cm in diameter, tumor-bearing mice were systemically administered (64)Cu

151 The greatest effect occurred when tumor-bearing mice were treated with curcumin prior to I

152 Tumor-bearing mice were treated with JQ1 (50 mg/kg daily

153 y, in the murine model, approximately 40% of tumor-bearing mice were tumor-free after a single treatm

154 Summary In the study of Zhang et al (1), tumor-bearing mice were vaccinated with magnetically lab

155 acid metabolism, and methylation, identified tumor-bearing mice with 100% accuracy, and also accurate

156 We demonstrate that treatment of tumor-bearing mice with a blocking anti-M-CSFR monoclona

157 In parallel, tumor-bearing mice with access to running wheels showed

158 Treating tumor-bearing mice with agents that block mast cell migr

159 essing mouse model of melanoma, treatment of tumor-bearing mice with alphaGC/OVA-loaded exosomes decr

160 T cell responses upon systemic treatment of tumor-bearing mice with antimalarial drugs.

161 1 immunity in CNS tissues, we infected GL261 tumor-bearing mice with attenuated rabies virus (RABV).

162 istribution studies were performed in LS174T tumor-bearing mice with AVP04-07-TCO(n) (where n indicat

163 ollowing transplantation, and inoculation of tumor-bearing mice with bFGF markedly inhibits tumor gro

164 Treatment of tumor-bearing mice with different chemotherapeutics resu

165 e observed that the single-dose treatment of tumor-bearing mice with DMA 2 hours before 8 Gy total bo

166 omparison of non-draining LNs and spleens of tumor-bearing mice with LNs and spleens from naive mice

167 Furthermore, treatment of E.G7-OVA tumor-bearing mice with Lp/OVA/StII significantly reduce

168 Pancreatic tumor-bearing mice with luciferase-transduced S2VP10L tu

169 efects in tumors can be reversed by treating tumor-bearing mice with multivalent forms of the Notch r

170 ncing in MCL cells and prolonged survival of tumor-bearing mice with no observed adverse effects.

171 s mechanism of action is preserved, to treat tumor-bearing mice with otherwise lethal levels of chemo

172 Similarly, treatment of ovarian tumor-bearing mice with PD-1 blocking antibody resulted

173 Treatment of tumor-bearing mice with PT2385 caused dramatic tumor reg

174 y decreased tumor weight and splenomegaly in tumor-bearing mice with reduced accumulation of polymorp

175 P78-regulated metabolite changes by treating tumor-bearing mice with tamoxifen and/or linoleic acid.

176 ted blood, splenic and intratumoral MDSCs in tumor-bearing mice without affecting proinflammatory imm

177 tumor growth through apoptosis in NSCLC H460 tumor-bearing mice without nephrotoxicity.

178 omparison with controls after injection into tumor-bearing mice, and promoted DC maturation, leading

179 cessfully performed on tumor-bearing and non-tumor-bearing mice, as well as on controls bearing sites

180 foundly block naive CD8(+) T cell priming in tumor-bearing mice, but actually increased the number of

181 d in MDSCs isolated from cancer patients and tumor-bearing mice, but not in control neutrophils or mo

182 In tumor-bearing mice, elevated iNOS expression is a hallma

183 ngiogenesis, leading to improved survival of tumor-bearing mice, even when this interaction was intac

184 ection of the various SPIO compositions into tumor-bearing mice, inductively coupled plasma mass spec

185 In tumor-bearing mice, levels of miR486 were relatively red

186 For single Raji tumor-bearing mice, pretargeting with CD20-specific FP s

187 An OV engineered to express FGF2 was safe in tumor-bearing mice, showed improved therapeutic efficacy

188 select a higher ambient temperature than non-tumor-bearing mice, suggesting that tumor-bearing mice e

189 t those isolated from the spleen of the same tumor-bearing mice, suppress T cell proliferation and ex

190 Further, in tumor-bearing mice, UPI peptide markedly impaired functi

191 In tumor-bearing mice, we found that Tregs within the tumor

192 Using tumor-bearing mice, we provide proof of principle for se

193 e prolonged survival but did not cure HDLM-2 tumor-bearing mice, whereas BV combined with ruxolitinib

194 D-1-expressing cells extends the survival of tumor-bearing mice, whereas free drugs have no effect at

195 o(LA)8-PTX induced tumor regression in A549 tumor-bearing mice, whereas PTX delayed tumor growth.

196 high-dimensional analysis of immune cells in tumor-bearing mice, which eliminates gating biases and i

197 (64)Cu-DOTA-cetuximab in KRAS-mutated HCT116 tumor-bearing mice, with and without cisplatin, which up

198 er efficacy of cisplatin and radiotherapy in tumor-bearing mice.

199 metabolites cycling exclusively in livers of tumor-bearing mice.

200 icant elevation of circulating L-selectin in tumor-bearing mice.

201 icacy of PLD and conventional doxorubicin in tumor-bearing mice.

202 2-MZP B cells possess regulatory activity in tumor-bearing mice.

203 argeting correlated with reduced survival of tumor-bearing mice.

204 tive as paclitaxel in anticancer activity in tumor-bearing mice.

205 e effects on tumor growth in immunodeficient tumor-bearing mice.

206 TX014 on MDSC-mediated T-cell suppression in tumor-bearing mice.

207 overcoming established tumor suppression in tumor-bearing mice.

208 se uptake and attenuates tumor growth in HCC tumor-bearing mice.

209 ic tumor cell death and growth inhibition in tumor-bearing mice.

210 ying brain tumors and prolonging survival of tumor-bearing mice.

211 d to tumors, compared with splenic MDSC from tumor-bearing mice.

212 renewal and increased survival of orthotopic tumor-bearing mice.

213 d significantly extended the survival of 4T1 tumor-bearing mice.

214 and functional properties of immune cells in tumor-bearing mice.

215 oma growth and prolonged the survival of the tumor-bearing mice.

216 y or tumor-bearing animals and injected into tumor-bearing mice.

217 % of the mice and to metastases in 8% of the tumor-bearing mice.

218 significantly prolongs the survival of brain tumor-bearing mice.

219 HPV E7 protein caused tumor rejection in all tumor-bearing mice.

220 tribution of (89)Zr-labeled PRS-110 in human tumor-bearing mice.

221 specific uptake both in vitro and in vivo in tumor-bearing mice.

222 arginine), were also increased in urine from tumor-bearing mice.

223 increased following doxorubicin treatment of tumor-bearing mice.

224 anced vaccine-induced protective immunity in tumor-bearing mice.

225 atment outcomes, curing more than 80% of the tumor-bearing mice.

226 itumor immunity and suppress tumor growth in tumor-bearing mice.

227 ectively, increasing the overall survival of tumor-bearing mice.

228 ECT imaging experiments were performed in KB tumor-bearing mice.

229 ce of MDSCs and improved immune responses in tumor-bearing mice.

230 Dynamic scans were also obtained for B16F10 tumor-bearing mice.

231 In vivo VRF PEDRI was performed on Met-1 tumor-bearing mice.

232 n vitro and in the plasma and lungs of fs120 tumor-bearing mice.

233 enesis of cachexia-induced muscle wasting in tumor-bearing mice.

234 ion, and therapeutic efficacy in healthy and tumor-bearing mice.

235 e up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice.

236 /group) was performed in wild-type and MM1.S tumor-bearing mice.

237 ic to significantly increase the lifespan of tumor-bearing mice.

238 growth and prolongs the overall survival of tumor-bearing mice.

239 triggered rejection of ID8 tumors in 75% of tumor-bearing mice.

240 OPC-315P myeloma cells in the bone marrow of tumor-bearing mice.

241 ematopoietic cells within the bone marrow of tumor-bearing mice.

242 epeated waves of ACT T-cell proliferation in tumor-bearing mice.

243 apoptosis and decreased MDSC accumulation in tumor-bearing mice.

244 also necessary for effective PD-1 therapy in tumor-bearing mice.

245 udies were performed in both B16F10 and A375 tumor-bearing mice.

246 tic Ccl2 reduction prolonged the survival of tumor-bearing mice.

247 while maintaining the antitumor efficacy in tumor-bearing mice.

248 improved anti-tumor efficacy in vivo in 4T1 tumor-bearing mice.

249 are greatly expanded in cancer patients and tumor-bearing mice.

250 uppressor cells in early metastatic sites of tumor-bearing mice.

251 gonal click reaction in cell cultures and in tumor-bearing mice.

252 mation compared with wildtype littermates in tumor-bearing mice.

253 ice and by competitive blocking in wild-type tumor-bearing mice.

254 -MDSCs, with reduced tumor burden in 4T1-Neu tumor-bearing mice.

255 opoietic stem and progenitor cells (HSPC) in tumor-bearing mice.

256 gene products compared with macrophages from tumor-bearing MIF wild-type mice.

257 in vivo studies using LS174T s.c. xenograft tumor bearing mouse, selective and significantly augment

258 In a tumor-bearing mouse injected with 3 MBq of [(213)Bi-DOTA

259 "exposed" surface labeled variants in a CT26 tumor-bearing mouse model.

260 inally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performed.

261 of gold nanoparticles (GNPs) injected into a tumor-bearing mouse.

262 tween the two and for selective resection of tumor-bearing nodes using Cerenkov imaging.

263 atment of orthotopic human pancreatic cancer tumor-bearing NSG mice with activated NK cells led to si

264 We have shown that the non-tumor-bearing (NT), recombinant adeno-associated virus (

265 all-animal PET experiments were performed on tumor-bearing nude mice after subcutaneous injection of

266 so evaluated in HCC827, H1975, H358 and H520 tumor-bearing nude mice by PET/CT imaging.

267 In 4T1 tumor-bearing nude mice that received intratumoral or in

268 vitro in PC-3 cell line and in vivo in PC-3 tumor-bearing nude mice.

269 y to measure the stiffness of healthy versus tumor-bearing optic nerve tissue.

270 average elastic moduli of non-neoplastic and tumor-bearing optic nerves were approximately 3 and appr

271 nistration of into hepatic arteries of a VX2 tumor-bearing rabbit under fluoroscopy, followed by subs

272 Fifteen VX2-tumor-bearing rabbits were assigned to three groups depe

273 injections of rat hepatoma cells (H4IIE); 24 tumor-bearing rats (mean tumor diameter, approximately 1

274 (dox) and [Gd(HPDO3A)(H2O)], and injected in tumor-bearing rats before MR-HIFU treatment.

275 Greater neuroinflammatory responses in tumor-bearing rats were accompanied by attenuated body w

276 a and CD11b mRNA expression were elevated in tumor-bearing rats, whereas Ido expression was reduced.

277 tory pathways are potentiated, or primed, in tumor-bearing rats, which may exacerbate future negative

278 sue obtained from breast cancer patients and tumor-bearing rats.

279 enables assessment of ERbeta availability in tumor-bearing rats.

280 red from DGKzeta-deficient mice to wild-type tumor-bearing recipients conferred this benefit.

281 greater in hippocampus and frontal cortex of tumor-bearing relative to tumor-free rats, IkappaBalpha

282 ted tumor-bearing immunocompetent hosts into tumor-bearing SCID-NOD immunocompromised mice attenuated

283 in PD-L1-positive, PD-L1-negative, and mixed tumor-bearing severe combined immunodeficiency mice.

284 opeptide alone or after coinjection of PA in tumor-bearing severe combined immunodeficient (SCID) mic

285 the in vivo antitumor effects of MEDI-575 in tumor-bearing severe combined immunodeficient (SCID) mic

286 -4 radioconjugates were investigated in PC-3 tumor-bearing severely combined immunodeficient mice.

287 ify transcriptional programs associated with tumors bearing specific genetic driver alterations.

288 epletion of CD4(+) but not CD8(+) T cells in tumor-bearing subjects reversed the inhibitory effects o

289 ve change in reporter levels also identified tumor-bearing subjects, and a receiver operator-characte

290 etectable in the blood nearly exclusively in tumor-bearing subjects.

291 outcomes elicited by bacterial infections in tumor-bearing subjects.

292 ed with 2 x 10(7) of Walker 256 tumor cells [tumor bearing (TB) rats].

293 tumor, and how the profile compares with non-tumor-bearing tissues.

294 Critically, LLC tumor-bearing TLR4(-/-) mice were spared from muscle was

295 ro and accelerated metastatic progression in tumor-bearing TRAMP mice.

296 pression of cytokines, such as IL1beta, from tumor-bearing versus unseeded scaffolds.

297 ash mice into line 1 alveolar cell carcinoma tumor-bearing wild-type littermates leads to enhanced tu

298 in tumor-bearing MerTK-/- mice compared with tumor-bearing wild-type mice.

299 HCC1954 tumor-bearing xenograft models were established, and (18

300 As large cohorts of brain tumor-bearing zebrafish can be generated rapidly and ine